The Latest Analyst Ratings for Cytek Biosciences
Portfolio Pulse from Benzinga Insights
Cytek Biosciences (NASDAQ:CTKB) received 4 analyst ratings in the last quarter, with 2 somewhat bullish and 2 indifferent, and no bearish ratings. The average 12-month price target is $8.5, with a high of $10.00 and a low of $7.00, marking a 29.17% decrease from the previous target of $12.00.
December 14, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cytek Biosciences received mixed analyst ratings with an average 12-month price target of $8.5, a decrease from the previous $12.00 target.
The mixed analyst ratings with a decreased price target suggest a neutral short-term impact on CTKB's stock price. The lack of bearish ratings indicates no strong negative sentiment, while the decrease in the price target may temper investor expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100